Empros Pharma AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.emprospharma.com
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
Phase 1
Recruiting
- Conditions
- Overweight or Obesity
- Interventions
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Empros Pharma AB
- Target Recruit Count
- 20
- Registration Number
- NCT06013163
- Locations
- 🇸🇪
CTC Clinical Trial Consultanta AB, Uppsala, Sweden
Study Exploring the Supportive Effect of Acarbose in Weight Management
Phase 2
Active, not recruiting
- Conditions
- Overweight or Obesity
- Interventions
- Drug: EMP16-120/40Drug: MR orlistat 120 mgDrug: Conventional orlistat 120 mg,Drug: EMP16-60/20Drug: Placebo
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Empros Pharma AB
- Target Recruit Count
- 320
- Registration Number
- NCT05934110
- Locations
- 🇸🇪
Clinical Trial Consultants (CTC), Uppsala,, Sweden
🇸🇪CTC Ebbepark, Linköping, Sweden
🇸🇪CTC Karolinska, Solna, Sweden
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
Phase 1
Completed
- Conditions
- Overweight or Obesity
- Interventions
- Drug: EMP16-02 120 mg orlistat/40 mg acarboseDrug: EMP16-02 150 mg orlistat/50 mg acarboseDrug: Placebo
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Empros Pharma AB
- Target Recruit Count
- 156
- Registration Number
- NCT04521751
- Locations
- 🇸🇪
Clinical Trial Consultants AB, Uppsala, Sweden
© Copyright 2025. All Rights Reserved by MedPath